PleuraSeal Post Market Study (Europe)

This study has been completed.

Sponsor:

Collaborator:

Covidien

Information provided by:

Integra LifeSciences Corporation

ClinicalTrials.gov Identifier:

NCT00704171

First received: June 23, 2008

Last updated: September 4, 2014

Last verified: September 2014

History of Changes

Results First Received: December 21, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Single Blind (Subject); Primary Purpose: Treatment
Conditions:	Lung Disease Pulmonary Lobectomy
Interventions:	Procedure: Standard Tissue Closure Techniques Device: PleuraSeal Lung Sealant System

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between January 28, 2008 and October 21, 2008, a total of 161 subjects were consented and screened for potential study participation at 8 institutions (hospitals). Of these subjects, 121 were randomized.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects were evaluated for pre-operative and intra-operative eligibility criteria. Randomization occurred intra-operatively.

Reporting Groups

	Description
PleuraSeal	PleuraSeal Lung Sealant System
Standard of Care	Standard tissue closure techniques (control) - sutures or staples only

Participant Flow: Overall Study

	PleuraSeal	Standard of Care
STARTED	62	59
COMPLETED	61 ^[1]	59 ^[2]
NOT COMPLETED	1	0
Withdrawal by Subject	1	0

[1]	One subject withdrew consent prior to study completion. No reason given.
[2]	All control subjects completed the study.

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
PleuraSeal	PleuraSeal Lung Sealant System
Standard of Care	Standard tissue closure techniques (control) - sutures or staples only
Total	Total of all reporting groups

Baseline Measures

	PleuraSeal	Standard of Care	Total
Number of Participants [units: participants]	62	59	121
Age [units: years] Mean ± Standard Deviation	61.5 ± 9.1	62.8 ± 10.8	62.1 ± 9.9
Gender [units: participants]
Female	26	22	48
Male	36	37	73
Race/Ethnicity, Customized [units: participants]
Caucasian	61	55	116
African	0	1	1
Asian	0	1	1
Hispanic	0	1	1
Other	1	1	2
Region of Enrollment [units: participants]
Netherlands	9	6	15
Belgium	14	14	28
United Kingdom	6	4	10
Austria	32	30	62
Switzerland	1	5	6
Nicotine Use [units: participants]
History	31	34	65
Current	22	17	39
Never	9	8	17
Body Mass Index [units: kg/m^2] Mean ± Standard Deviation	25.86 ± 4.73	26.35 ± 4.55	26.10 ± 4.63
Height [units: cm] Mean ± Standard Deviation	169.5 ± 8.8	169.4 ± 9.6	169.4 ± 9.1
Weight [units: kg] Mean ± Standard Deviation	74.46 ± 15.35	75.57 ± 13.96	75.00 ± 14.64

Outcome Measures

Show All Outcome Measures

1. Primary:

Percentage of Subjects Remaining Air Leak Free From Time of Skin Closure to Hospital Discharge. [ Time Frame: 30 days ]

Show Outcome Measure 1

2. Primary:

Percentage of Subjects Remaining Air Leak Free From Skin Closure to Discharge [ Time Frame: 30 days ]

Show Outcome Measure 2

3. Secondary:

Percentage of Subjects for Whom Intra-operative Air Leak Sealing Success is Achieved. [ Time Frame: Intra-operatively, time of study procedure ]

Show Outcome Measure 3

4. Secondary:

Time From Skin Closure to Last Observable Air Leak. [ Time Frame: 30 days ]

Show Outcome Measure 4

5. Secondary:

Duration of Chest Drainage [ Time Frame: 30 days ]

Show Outcome Measure 5

6. Secondary:

Duration of Hospitalization [ Time Frame: 30 days ]

Show Outcome Measure 6

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Institution and Investigator agree to submit the draft of any proposed publication to Sponsor at least 30 dyas prior to submission for publication, presentation, or use, and agrees, at the request of the Sponsor, to withhold any such submission for an additional period, not to exceed 90 days to allow Sponsor to file patent applications. The first publication of the results shall be made in conjunction with the presentation of a joint, multi-center publication.

Results Point of Contact:

Name/Title: Jennifer L. Doyle, Global Director of Clinical Affairs
Organization: Covidien
phone: 781-839-1770
e-mail: jennifer.doyle@covidien.com

No publications provided

Responsible Party:	Jennifer Doyle - Director, Clinical Affairs, Confluent Surgical / Covidien
ClinicalTrials.gov Identifier:	NCT00704171 History of Changes
Other Study ID Numbers:	LUN-06-002
Study First Received:	June 23, 2008
Results First Received:	December 21, 2009
Last Updated:	September 4, 2014
Health Authority:	Belgium: Institutional Review Board

To Top